Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients

[1]  L. Gieselmann,et al.  Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients , 2020, Cell.

[2]  X. Tang,et al.  Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections , 2020, Nature Medicine.

[3]  J. Sodroski,et al.  Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-CoV-2 Spike , 2020, bioRxiv.

[4]  R. Welsh,et al.  Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail , 2020, Science.

[5]  G. Atwal,et al.  Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies , 2020, Science.

[6]  D. Burton,et al.  Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.

[7]  J. Dye,et al.  Broad neutralization of SARS-related viruses by human monoclonal antibodies , 2020, Science.

[8]  C. Rice,et al.  Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.

[9]  L. Stamatatos,et al.  Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation , 2020, Immunity.

[10]  B. Haynes,et al.  Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19 , 2020, Cell.

[11]  William J. Liu,et al.  A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 , 2020, Nature.

[12]  Linqi Zhang,et al.  Human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, Nature.

[13]  Lisa E. Gralinski,et al.  Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals , 2020, bioRxiv.

[14]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[15]  Yanhu Li,et al.  Isolation of and Characterization of Neutralizing Antibodies to Covid-19 from a Large Human Naïve scFv Phage Display Library , 2020, bioRxiv.

[16]  X. Xie,et al.  Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells , 2020, Cell.

[17]  Amalio Telenti,et al.  Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.

[18]  Lisa E. Gralinski,et al.  Potent neutralization of SARS-CoV-2 in vitro and in an animal model by a human monoclonal antibody , 2020, bioRxiv.

[19]  Lisa E. Gralinski,et al.  Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models , 2020 .

[20]  D. Burton,et al.  Rational Vaccine Design in the Time of COVID-19 , 2020, Cell Host & Microbe.

[21]  M. V. van Breemen,et al.  Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.

[22]  R. Rappuoli,et al.  Identification of neutralizing human monoclonal antibodies from Italian Covid-19 convalescent patients , 2020, bioRxiv.

[23]  F. Gao,et al.  A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 , 2020, Science.

[24]  Hongbing Shen,et al.  Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection , 2020, bioRxiv.

[25]  Hongbing Shen,et al.  Isolating multiple formats of human monoclonal neutralizing antibodies against SARS-CoV-2 by in vitro site-directed antibody screening , 2020 .

[26]  Xinquan Wang,et al.  Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals , 2020, Immunity.

[27]  X. Tang,et al.  Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.

[28]  U. Reimer,et al.  Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors , 2020, medRxiv.

[29]  Jianhua Du,et al.  Blocking antibodies against SARS-CoV-2 RBD isolated from a phage display antibody library using a competitive biopanning strategy , 2020, bioRxiv.

[30]  M. Addo,et al.  Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial , 2020, The Lancet Infectious Diseases.

[31]  Kaijun Jiang,et al.  SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup , 2020, Current protocols in microbiology.

[32]  T. Jodlowski,et al.  Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.

[33]  Yan Peng,et al.  Effectiveness of convalescent plasma therapy in severe COVID-19 patients , 2020, Proceedings of the National Academy of Sciences.

[34]  N. Callewaert,et al.  Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies , 2020, Cell.

[35]  Frank Grosveld,et al.  A human monoclonal antibody blocking SARS-CoV-2 infection , 2020, Nature Communications.

[36]  D. Watkins,et al.  Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine , 2020, Proceedings of the National Academy of Sciences.

[37]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[38]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[39]  Young-Jun Park,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[40]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[41]  E. Dong,et al.  An interactive web-based dashboard to track COVID-19 in real time , 2020, The Lancet Infectious Diseases.

[42]  B. Graham,et al.  Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation , 2020, bioRxiv.

[43]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[44]  Nico Pfeifer,et al.  openPrimeR for multiplex amplification of highly diverse templates. , 2020, Journal of immunological methods.

[45]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[46]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[47]  J. Bloom,et al.  Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody , 2020, Cell.

[48]  T. Mora,et al.  Exploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination Strategies , 2020, Vaccines.

[49]  J. Sodroski,et al.  SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease , 2020, bioRxiv.

[50]  Daniel Edler,et al.  raxmlGUI 2.0 beta: a graphical interface and toolkit for phylogenetic analyses using RAxML , 2019, bioRxiv.

[51]  M. Addo,et al.  Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV , 2019, Nature Medicine.

[52]  Chaim A. Schramm,et al.  Activation Dynamics and Immunoglobulin Evolution of Pre-existing and Newly Generated Human Memory B cell Responses to Influenza Hemagglutinin. , 2019, Immunity.

[53]  A. Trkola,et al.  Correlates of broadly neutralizing antibody development. , 2019, Current opinion in HIV and AIDS.

[54]  S. Zolla-Pazner,et al.  Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV , 2019, Current opinion in HIV and AIDS.

[55]  J. Sidney,et al.  Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection , 2019, Cell.

[56]  J. Dye,et al.  Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection , 2018, Cell.

[57]  D. Burton,et al.  Passive immunotherapy of viral infections: 'super-antibodies' enter the fray , 2018, Nature Reviews Immunology.

[58]  Tongqing Zhou,et al.  Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. , 2016, Immunity.

[59]  M. Nussenzweig,et al.  Sequencing and cloning of antigen-specific antibodies from mouse memory B cells , 2016, Nature Protocols.

[60]  Cinque S. Soto,et al.  Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses , 2016, Cell.

[61]  P. Collins,et al.  Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes , 2016, Cell.

[62]  Jian Yu,et al.  Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity , 2016, Cell.

[63]  James E. Crowe,et al.  Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection , 2016, Cell.

[64]  A. Fauci,et al.  Toward an HIV vaccine: A scientific journey , 2015, Science.

[65]  R. Marschalek,et al.  Optimized Sleeping Beauty transposons rapidly generate stable transgenic cell lines. , 2015, Biotechnology journal.

[66]  David A. Hafler,et al.  pRESTO: a toolkit for processing high-throughput sequencing raw reads of lymphocyte receptor repertoires , 2014, Bioinform..

[67]  Alexandros Stamatakis,et al.  RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies , 2014, Bioinform..

[68]  Florian Klein,et al.  Antibodies in HIV-1 Vaccine Development and Therapy , 2013, Science.

[69]  Philip R. Johnson,et al.  Accelerating Next-Generation Vaccine Development for Global Disease Prevention , 2013, Science.

[70]  Ning Ma,et al.  IgBLAST: an immunoglobulin variable domain sequence analysis tool , 2013, Nucleic Acids Res..

[71]  Michael Meyer-Hermann,et al.  Germinal center B cells govern their own fate via antibody feedback , 2013, The Journal of experimental medicine.

[72]  D. Higgins,et al.  Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega , 2011, Molecular systems biology.

[73]  Ron Diskin,et al.  Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.

[74]  J. Skehel,et al.  A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins , 2011, Science.

[75]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[76]  David C Montefiori,et al.  The role of antibodies in HIV vaccines. , 2010, Annual review of immunology.

[77]  Andreas Radbruch,et al.  Generation of stable monoclonal antibody-producing BCR+ human memory B cells by genetic programming , 2009, Nature Medicine.

[78]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[79]  D. Eisenberg,et al.  Analysis of membrane and surface protein sequences with the hydrophobic moment plot. , 1984, Journal of molecular biology.

[80]  H. Kowarzyk.  Structure and Function. , 1910, Nature.

[81]  Captain Y. B. Nusfield,et al.  Public Health , 1906, Canadian Medical Association journal.

[82]  Feng-hua Liu,et al.  A systematic analysis , 2020 .

[83]  Michel C Nussenzweig,et al.  Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. , 2008, Journal of immunological methods.

[84]  James R. Harris,et al.  LONGITUDINAL DYNAMICS IN THE , 2005 .

[85]  Hua,et al.  Identification of , 2000, Journal of insect physiology.

[86]  D. Sommers,et al.  A longitudinal analysis , 1992 .

[87]  F. Shlaeffer,et al.  [Viral hemorrhagic fever]. , 1988, Harefuah.

[88]  W. Mackenzie.  Analysis of Memory , 1902, Nature.